Novonesis CEO Ester Baiget told CNBC that dietary supplements could become the next major growth sector tied to the GLP‑1 weight‑loss drug boom. The biotech firm is testing a “unique cocktail” of pro‑, pre‑ and post‑biotics designed to improve gut microbiome health for patients taking GLP‑1 medicines such as Novo Nordisk’s Wegovy and Ozempic. Baiget emphasized that scientific validation of these supplements would create strong market demand, positioning them as a therapeutic companion to the drugs.

The discussion highlighted the complementary roles of pharmacology and nutrition in tackling obesity. While GLP‑1 agents deliver rapid weight reduction, Baiget argued that long‑term health outcomes may depend on supporting gut flora, which influences metabolism, appetite regulation, and inflammation. Novonesis is currently running a study in partnership with Novo Nordisk to assess whether microbiome‑targeted supplements can enhance patient well‑being and adherence during GLP‑1 treatment, potentially opening a new revenue stream for both companies.

The broader weight‑loss market, dominated by Novo Nordisk and U.S. rival Eli Lilly, has generated billions of dollars in sales and attracted intense investor interest. If Novonesis’s microbiome supplement platform proves effective, it could capture a share of the ancillary market, offering investors a novel exposure point beyond the headline‑grabbing GLP‑1 drugs themselves.